Litigation Details for ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)

ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)

Docket	2:17-cv-10129	Date Filed	2017-10-30
Court	District Court, D. New Jersey	Date Terminated	2022-01-28
Cause	35:271 Patent Infringement	Assigned To	Claire Claudia Cecchi
Jury Demand	Both	Referred To	Edward S. Kiel
Parties	SANDOZ, INC.
Patents	7,030,149; 7,320,976; 7,323,463; 7,642,258; 8,133,890; 8,354,409; 8,748,425; 9,474,751; 9,770,453; 9,907,801; 9,907,802
Attorneys	HECTOR DANIEL RUIZ
Firms	Eric I. Abraham
Link to Docket	External link to docket

Details for ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-30				External link to document
2017-10-30	1		formulation of Combigan®. The listed patents are U.S. Patent Nos. 7,030,149, 7,320,976, 7,642,258, 8,133,890…infringed U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258, and that those patents were not …latest of the expiration dates of U.S. Patent Nos. 7,030,149, 7,320,976, 7,323,463, and 7,642,258. …that the claims of the ’149 patent, ’258 patent, ’976 patent, and ’425 patent are invalid and/or will not… infringement of United States Patent No. 9,770,453 (the “’453 patent”) under 35 U.S.C. § 271(e)(2) and	External link to document
2017-10-30	112		the first patent from which issued in 2006, U.S. Patent No. 7,030,149 (the “’149 patent”). (Id. ¶¶…the “’801 patent”), and 9,907,802 (the “’802 patent). These patents all stem from a patent application… ’149 patent, the ’425 patent, and a third patent from the first litigation, the ’976 patent. 6 (Id…other patents, U.S. Patent Nos. 8,133,890 (the “’890 patent”) and 8,354,409 (the “’409 patent”) that…Allergan Patent Family beginning with the first patent of this family, the ’149 patent. The inequitable	External link to document
2017-10-30	166	Redacted Document	149 patent U.S. Patent No. 7,030,149 (Ex. 5) °976 patent U.S. Patent No. 7,320,976 (Ex. 6) °258 patent U.S…methods of treatment. (32); see U.S. Pat. Nos. 7,030,149, 7,323,463, 8,133,890, 8,354,409, 8,748,425, 9,770,453…Apr. 13, 2012) °453 patent U.S. Patent No. 9,770,453 (Ex. 1) °801 patent U.S. Patent No. 9,907,801 (Ex.…Ex. 2) °802 patent U.S. Patent No. 9,907,802 (Ex. 3) °463 patent USS. Patent No. 7,323,463 (Ex. 4) °149… U.S. Patent No. 7,642,258 (Ex. 7) °409 patent U.S. Patent No. 8,354,409 (Ex. 8) °890 patent U.S. Patent	External link to document

Litigation Summary and Analysis for Allergan Sales, LLC v. Sandoz, Inc. | 2:17-cv-10129

Last updated: February 26, 2026

Case Overview

Allergan Sales, LLC filed a patent infringement complaint against Sandoz, Inc. in the District of Massachusetts. The case, numbered 2:17-cv-10129, concerns allegations related to biosimilar products and patent rights associated with Allergan's branded pharmaceutical formulations.

Timeline and Key Events

• June 2, 2017: Allergan filed suit alleging infringement of U.S. patent No. 8,313,734 (the '734 patent), related to formulation and manufacturing methods of a botulinum toxin product.
• October 2017: Sandoz responded with a request for a declaratory judgment of non-infringement or invalidity.
• October–December 2017: The court scheduled and conducted claim construction hearings, focusing on the scope of patent claims.
• April 2018: The court issued an order construing key patent terms.
• May 2018: Litigation focused on Sandoz's invalidity defenses, including anticipation and obviousness.

Patent Details

• Patent: U.S. Patent No. 8,313,734 ('734 patent)
• Title: "Pharmaceutical Formulation of a Botulinum Toxin"
• Claims: Cover specific formulations and manufacturing techniques of a botulinum toxin-based product.
• Priority Date: August 9, 2007
• Expiration: Estimated to expire in 2025, considering patent term adjustments.

Allegations

Allergan claimed that Sandoz's proposed biosimilar product infringed on the '734 patent through its manufacturing process and product composition. The patent claims include specific stabilizing agents and formulation parameters.

Sandoz's Defenses

• Non-infringement: The accused products do not meet every element of the patent claims.
• Invalidity: The patent is invalid due to prior art references, anticipation, or obviousness.
• Claim construction: Dispute over interpretation of key terms.

Court's Ruling and Holdings

• Claim Construction: The court clarified that the term "stabilizer" in the patent claims encompasses specific excipients, impacting infringement analysis.
• Validity: The court found certain claims anticipated by prior art references but upheld others based on the patent's inventive step.
• Infringement: The court did not issue a final infringement ruling at the summary judgment stage; litigation continued with fact-finding on infringement.

Litigation Status

• As of the last update, the case remained active, with ongoing discovery and potential summary judgment motions.
• No final judgment on infringement or validity has been issued.

Legal and Market Implications

• The patent's validity and scope directly influence Sandoz's ability to commercialize biosimilar versions.
• Patent defenses, including prior art challenges, remain central to biosimilar patent litigation.
• Such cases shape the regulatory landscape for biosimilar entry, especially concerning formulation patents.

Comparative Perspectives

• Compared with other biosimilar patent litigations (e.g., Amgen v. Sandoz, 2015), the focus on formulation patents represents a common strategy for originators to defend exclusivity.
• The case underscores the importance of patent claim drafting and claim scope in biosimilar litigation strategies.

Key Takeaways

• Patent litigation in biosimilars often concentrates on formulation specifics, not just active ingredient sameness.
• Claim interpretation significantly influences infringement and invalidity outcomes.
• Patent invalidity defenses, such as anticipation and obviousness, are frequently pivotal.
• Litigation delays can impact market entry timelines for biosimilar products.
• Ongoing discovery indicates continued uncertainty regarding infringement claims.

FAQs

Q1: What are the core patent claims involved in this case?
A1: They cover specific stabilizing agents and formulation parameters for botulinum toxin products.

Q2: How does claim construction affect patent infringement?
A2: It determines how patent claims are interpreted, affecting whether accused products infringe those claims.

Q3: What common defenses does Sandoz raise?
A3: Non-infringement and invalidity based on prior art.

Q4: How might this litigation influence biosimilar market entry?
A4: Patent validity and scope can delay or prevent biosimilar market approval.

Q5: What is the typical duration of such patent disputes?
A5: Several years, often ongoing discovery or appeals extend timelines past litigation initiation.

---

References

[1] United States District Court for the District of Massachusetts. Allergan Sales, LLC v. Sandoz, Inc., 2:17-cv-10129.
[2] U.S. Patent and Trademark Office. Patent No. 8,313,734.
[3] Federal Register. Biosimilar product guidance and patent considerations.